VII-31
Based on 2 publication(s) in Google Scholar
VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.63%
- CAS No.: 2305757-96-2
- Formule: C23H25NO5S
- Masse moléculaire:427.51
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Oxygen Sensing Compound Library
HY-L045
-
Ubiquitination Compound Library
HY-L050
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) VII-31
More
Activité biologique
NEDDylation[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
0.1 μM
Compound: VII-31
|
Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
|
[PMID: 32135407] |
| MGC-803 | IC50 |
0.09 μM
Compound: VII-31
|
Antiproliferative activity against human MGC-803 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells measured after 48 hrs by MTT assay
|
[PMID: 32135407] |
| PC-3 | IC50 |
1.15 μM
Compound: VII-31
|
Antiproliferative activity against human PC-3 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells measured after 48 hrs by MTT assay
|
[PMID: 32135407] |
VII-31 (100 nM, 200 nM; 48 hours) inhibits the cell viability of gastric cell line MGC803 with an IC50 of 0.09±0.01 μM. VII-31 also inhibits the cell viability of MCF-7 and PC-3 with IC50s of 0.10±0.006 and 1.15±0.28μM , respectively[1].
VII-31 (50-150 nM; 24 hours) arrests MGC803 cells cycle in G2/M phase[1].
VII-31 (50-150 nM; 48 hours) induces apoptosis via intrinsic and extrinsic pathways[1].
VII-31 (50-150 nM; 24 hours) activates NEDDylation in MGC803 cells[1].
VII-31 (50-150 nM; 48 hours) up-regulates pro-apoptotic proteins FADD, Fasl, PIDD, Bax, Bad; while down-regulates anti-apoptotic proteins Bcl-xL, Bcl-2, XIAP, c-IAP1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Gastric cancer MGC803 cells
-
Concentration:100, 200 nM
-
Incubation Time:48 hours
-
Result:Inhibited the cell viability in dose-depend manner.
-
Cell Line:MGC803 cells
-
Concentration:50, 100, 150 nM
-
Incubation Time:24 hours
-
Result:Arrested cells in G2/M phase, and a clear sub-G1 peak was observed in the high dose group.
-
Cell Line:MGC803 cells
-
Concentration:50, 75, 100, and 150 nM
-
Incubation Time:48 hours
-
Result:High dose (150 nM) treatment significantly elevated the early and late apoptosis rate to 92.8% from 4.8%.
-
Cell Line:MGC803 cells
-
Concentration:50, 100, 150 nM
-
Incubation Time:24 hours
-
Result:Resulted in NEDDylation activation of MGC803 cells, the NEDDylation of 3 important proteins NAE1, Ubc12 and CUL1 has been activated.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice bearing MGC803 xenograft tumors[1]
-
Dosage:50, 100, 150 mg/kg
-
Administration:Subcutaneous injection; daily for 28 days
-
Result:The mice had a much smaller tumor compared with vehicle control. The tumor volumes of middle/high dose treated mice at certain time points were evidently decreased comparing with untreated group.
Chemical Information
-
CAS No. 2305757-96-2
-
Appearance Solid
-
Masse moléculaire 427.51
-
Formule C23H25NO5S
-
Color White to off-white
-
SMILES
O=C(CC1=CC=CS1)N(CC2=CC=C(OC)C=C2)C3=CC(OC)=C(OC)C(OC)=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia. [Abstract]2025 May 30;15(1):18978. PMID: 40447744 -
J Anim Sci
Ubiquitination plays an important role during the formation of chicken primordial germ cells. [Abstract]2024 Jan 3:102:skae251. PMID: 39187982
Solvant et solubilité
DMSO : 250 mg/mL (584.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.87 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3391 mL | 11.6956 mL | 23.3913 mL | 58.4782 mL |
| 5 mM | 0.4678 mL | 2.3391 mL | 4.6783 mL | 11.6956 mL | |
| 10 mM | 0.2339 mL | 1.1696 mL | 2.3391 mL | 5.8478 mL | |
| 15 mM | 0.1559 mL | 0.7797 mL | 1.5594 mL | 3.8985 mL | |
| 20 mM | 0.1170 mL | 0.5848 mL | 1.1696 mL | 2.9239 mL | |
| 25 mM | 0.0936 mL | 0.4678 mL | 0.9357 mL | 2.3391 mL | |
| 30 mM | 0.0780 mL | 0.3899 mL | 0.7797 mL | 1.9493 mL | |
| 40 mM | 0.0585 mL | 0.2924 mL | 0.5848 mL | 1.4620 mL | |
| 50 mM | 0.0468 mL | 0.2339 mL | 0.4678 mL | 1.1696 mL | |
| 60 mM | 0.0390 mL | 0.1949 mL | 0.3899 mL | 0.9746 mL | |
| 80 mM | 0.0292 mL | 0.1462 mL | 0.2924 mL | 0.7310 mL | |
| 100 mM | 0.0234 mL | 0.1170 mL | 0.2339 mL | 0.5848 mL |
VII-31 Related Classifications
HY-133558 Related Classifications
Powered by Bioz